JP2023535730A5 - - Google Patents
Info
- Publication number
- JP2023535730A5 JP2023535730A5 JP2023504555A JP2023504555A JP2023535730A5 JP 2023535730 A5 JP2023535730 A5 JP 2023535730A5 JP 2023504555 A JP2023504555 A JP 2023504555A JP 2023504555 A JP2023504555 A JP 2023504555A JP 2023535730 A5 JP2023535730 A5 JP 2023535730A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- cell
- formula
- permeable complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056465P | 2020-07-24 | 2020-07-24 | |
| US63/056,465 | 2020-07-24 | ||
| PCT/US2021/043213 WO2022020810A1 (en) | 2020-07-24 | 2021-07-26 | A three component vaccine for covid-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535730A JP2023535730A (ja) | 2023-08-21 |
| JP2023535730A5 true JP2023535730A5 (cg-RX-API-DMAC10.html) | 2024-05-27 |
Family
ID=79728449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504555A Pending JP2023535730A (ja) | 2020-07-24 | 2021-07-26 | Covid-19の3成分ワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240148858A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4185331A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023535730A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116724118A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021310952A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3189834A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022020810A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250177559A1 (en) * | 2022-03-09 | 2025-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Branched lipid charge-altering releasable transporters for nucleic acid delivery |
| EP4493197A4 (en) * | 2022-03-17 | 2026-03-18 | Univ Leland Stanford Junior | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN TRANSLATION FROM RECOMBED CIRCULAR RNA |
| US20260014246A1 (en) * | 2022-07-11 | 2026-01-15 | The Uab Research Foundation | Treatment methods for viral infections |
| CN121002058A (zh) * | 2022-12-09 | 2025-11-21 | 艾布维兹生物公司 | 针对SARS-CoV-2及其变体的抗体或其片段 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909915A (pt) * | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| EP3302501B1 (en) * | 2015-05-29 | 2021-09-22 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| JP7179715B2 (ja) * | 2016-07-27 | 2022-11-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 核酸送達用の崩壊性細胞透過性複合体 |
| US12215341B2 (en) * | 2018-11-09 | 2025-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Hybrid immolative cell-penetrating complexes for nucleic acid delivery |
| JP7693548B2 (ja) * | 2019-02-01 | 2025-06-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肺への核酸送達のための犠牲細胞透過性複合体 |
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
-
2021
- 2021-07-26 CN CN202180064754.1A patent/CN116724118A/zh active Pending
- 2021-07-26 EP EP21845716.6A patent/EP4185331A4/en not_active Withdrawn
- 2021-07-26 AU AU2021310952A patent/AU2021310952A1/en not_active Abandoned
- 2021-07-26 US US18/006,264 patent/US20240148858A1/en active Pending
- 2021-07-26 CA CA3189834A patent/CA3189834A1/en active Pending
- 2021-07-26 JP JP2023504555A patent/JP2023535730A/ja active Pending
- 2021-07-26 WO PCT/US2021/043213 patent/WO2022020810A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7625637B2 (ja) | B型肝炎ウイルス感染のためのRNAi薬 | |
| ES2572563T3 (es) | Oligonucleótidos inmunoestimulantes | |
| JP3273135B2 (ja) | 新規ペプチド核酸 | |
| JP7763907B2 (ja) | B型肝炎ウイルス感染のためのRNAi薬 | |
| BG109985A (bg) | Метод за лечение на астма, усложнена от инфекциозно заболяване | |
| JP2025072507A5 (cg-RX-API-DMAC10.html) | ||
| JP2020018299A (ja) | 修飾されたサブユニット間結合および/または末端基を有するオリゴヌクレオチドアナログ | |
| JP2003535146A5 (cg-RX-API-DMAC10.html) | ||
| CN111527207A (zh) | GalNAc衍生物 | |
| JP2011504486A5 (cg-RX-API-DMAC10.html) | ||
| AU2013262415B2 (en) | Oligonucleotide chelate complex methods | |
| CN110023321A (zh) | 多核苷酸构建体 | |
| EA008741B1 (ru) | Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью | |
| JP2006109846A (ja) | 抗腫瘍性アンチセンスオリゴヌクレオチド | |
| TWI298328B (en) | Polyamide nucleic acid derivatives, and agents and process for preparing them | |
| JP2022526267A5 (cg-RX-API-DMAC10.html) | ||
| JP2004501211A5 (cg-RX-API-DMAC10.html) | ||
| MXPA04000162A (es) | Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. | |
| JP2004526737A5 (cg-RX-API-DMAC10.html) | ||
| JP5428017B2 (ja) | ワクチン剤 | |
| CN119895041A (zh) | 优化的2’-修饰的核糖衍生物及使用方法 | |
| WO2020246584A1 (ja) | ペプチド核酸を基盤としたアジュバント | |
| WO2024163918A1 (en) | Mrna vaccine for herpes simplex virus | |
| WO2022215737A1 (ja) | アジュバント活性増強剤及びアジュバント組成物 | |
| JP2004522722A (ja) | 化合物 |